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Abstract
Intracellular-acting therapeutic proteins offer a promising clinical alternative to extracellular-
acting agents, but are limited in efficacy by their low permeability into the cell cytoplasm. We
have developed a nanoparticle (NP) composed of lipid (DOTAP/DOPE) and apolipoprotein (APO
A-I) to mediate the targeted delivery of intracellular-acting protein drugs to non-small cell lung
tumors. NPs were produced with either GFP, a fluorescent model protein, or cytochrome C (cytC),
an inducer of apoptosis in cancer cells. GFP and cytC were separately conjugated with a
membrane permeable sequence (MPS) peptide and were admixed with DOPE/DOTAP
nanoparticle formulations (NPs) to enable successful protein loading. Protein-loaded NPs were
modified with DSPE-PEG-Anisamide to enable specific NP targeting to the tumor site in a
xenograft model. The resulting particle was 20–30 nm in size and exhibited a 64–75% loading
efficiency. H460 cells treated with the PEGylated MPS-cytC-NPs exhibited massive apoptosis.
When MPS-GFP-NPs or MPS-cytC-NPs were intravenously administered in H460 tumor bearing
mice, a specific tumor targeting effect with low NP accumulation in the liver was observed. In
addition, MPS-cytC-NP treatment provoked a tumor growth retardation effect in H460 xenograft
mice. We conclude that our NP enables targeted, efficacious therapeutic protein delivery for the
treatment of lung cancer.
Introduction
Cancer originates from a deficiency or malfunction in somatic proteins participating in
cellular homeostasis. Therapies have been produced that treat cancer by silencing abnormal
cell signaling patterns using therapeutic proteins as inhibitors. Compared with gene
silencing agents, protein drugs have a rapid onset time and are therefore easily controlled by
specific dosing. However, manufactured therapeutic proteins are susceptible to proteolysis,
denaturation, and aggregation, limiting their efficacy in the body [1,2].
Nanoparticles have been shown to regulate the release of attached proteins based on the
degradation behavior of the NP constituent parts [3–5]. If a therapeutic protein is not highly
lipophilic, it is difficult to be encapsulated in this system. However, amphiphilic residues,
such as membrane permeable sequences (MPS), can be conjugated to non-lipophilic
proteins, including cytC or GFP, enabling these proteins to be associated into the lipid
bilayer of NPs [6]. A liposomal nanoparticle matrix offers beneficial protection against
enzymatic degradation and antibody neutralization, resulting in prolonged retention of
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attached protein activity in vivo for as long as the proteins remain complexed to their carriers
[7]. Recent research has also determined that nanoparticles conjugated with a cell
penetrating peptide (CPP) sequence have shown an increased ability to deliver drug cargo to
specific cell types after nonspecific, systematic treatment [8, 9].
Nano-size lipid bilayers have previously been developed to study the function of
biomembranes [10, 11]. Specifically, nanodiscs, or lipid bilayer nanostructures without
aqueous internal spaces, have shown potential for lipophilic drug delivery [12–13]. It has
been reported that nanodiscs can serve as easily modifiable matrices with a variable affinity
for protein drugs dependent on the relative proportions of lipid or introduced functional
group constituents [14].
Previously, we have developed several nano-carrier systems to deliver therapeutic cargoes
and have studied the protecting and targeting effect of drug carriers surface-modified with
target ligands and PEG [15–17]. In the current study, we have documented a delivery
platform that creates a nanoparticle constituted by small, refined lipid bilayers of
apolipoprotein and DOTAP/DOPE lipid. Our past results indicate that PEGylation and
incorporation of anisamide, a ligand that targets the sigma receptor over-expressed in H460
lung carcinoma, on the surface of the nanoparticle can enable successful evasion of RES-
induced, non-specific interactions in the liver [18–19]. In this study, we will detail the
therapeutic potential of this nanoparticle for delivering MPS-conjugated cytochrome C
therapeutic protein into H460 non-small cell lung carcinoma.
Materials and Methods
Characterization of MPS conjugated proteins, MPS-GFP-NPs, and MPS-cytC-NPs
MPS-conjugated protein drugs and NPs were created as described in further detail in the
Supplemental Information section. Briefly, MPS peptide (MPS: H-A-A-V-A-L-L-P-A-V-L-
L-AL-L-A-K-OH, 1548 MW from Anaspec, San Jose, CA) was activated with a 1:2 molar
ratio of protein:EDAC, and the resulting solution was dialyzed. GFP or cytC that had been
separately incubated with Alexa-488 succinimidyl esters (Invitrogen) was then reacted with
the activated MPS in a 1:2 molar ratio for six hours.
The DOTAP/DOPE/apoA-I nanoparticle was produced using a sodium cholate dialysis
method [20, 21]. Small unilamellar liposomes were prepared by mixing DOTAP and DOPE
(Avanti Polar Lipids, Inc) dissolved in chloroform in a 2:1 molar ratio (DOTAP:DOPE),
evaporating the solvent, then hydrating the mixture with Tris-HCL buffer and reacting the
liposomes with ApoA-I in a DOTAP:DOPE:apoA-I molar ratio of either 50:25:1 or 66:33:1.
The solution was incubated overnight until transparent and cholic acids were removed [21,
22]. The MPS-GFP or MPS-cytC proteins were then co-incubated with the particles for 1 h
to facilitate protein-NP coupling before PEGylation. The MPS-cytC loading efficiency in
the NPs was measured using a Sepharose CL-6B column (Amersham Biosciences, Uppsala,
Sweden). DSPE-PEG-anisamide was synthesized in our lab as described elsewhere [16, 19].
Targeted NPs were prepared by incubating the NP solution (238 µL) with a 15% micellar
solution of a 1:1 mixture of DSPE-PEG2000 and DSPE-PEG2000-anisamide (10 mg/mL), at
50 °C for 10 min.
Flow cytometry assay for detection of apoptosis
Estimation of apoptotic NCI-H460 lung cancer cell subpopulations was determined using
Annexin V-FITC and PI. Briefly, 1 ×105 cells per sample were washed with PBS, and then
were incubated in calcium binding buffer with 3 µL of Annexin V-FITC (0.5 mg/mL) for 20
min in darkness. Cells were washed with PBS, were suspended in 500 µL of calcium
binding buffer, then propidium iodide (PI) (5 mg/mL) was added and the samples were
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immediately analyzed by flow cytometry. All flow cytometric analyses were performed on a
BD FACS Canto™ flow cytometer (BD, RUO special order system, CA). A 20 mW blue
laser emitting a 488-nm beam served as the excitation source for Annexin V-FITC (FL1)
and PI (FL2). Annexin V (green) and PI (red) fluorescent signals were collected with 530
nm and 610 nm band pass filters, respectively, for 10,000 cells per sample.
Cell imaging by confocal microscopy
NCI-H460 cells were fixed with 2% paraformaldehyde after a 6 h exposure to Alexa488-
conjugated MPS-cytC-NPs and a subsequent 1 h incubation with MitoRed (red). Nuclei
were counterstained with DAPI (Sigma Aldrich, St. Louis, MO). Confocal images were
acquired with an SP2 Laser Scanning Confocal Microscope (Leica, Bannockburn, IL).
Tissue distribution and tumor uptake study
Female nude mice, 5–6 weeks old, were purchased from NCI. H460 xenograft tumor
bearing mice (size 40–50 mm2) were produced on the 6th day after injection of 5 × 106 NCI-
H460 cells on the rear side of the back of mice. In a preliminary study, mice exhibiting
tumors ~0.5 cm × 0.5 cm in size were i.v. injected with 160 µg/kg of the MPS-GFP or GFP
nanoparticles in different formulations. In a separate study, mice exhibiting the same size
tumors were i.v. injected with MPS-cytC or cytC NPs in different formulations (160 µg/kg).
After 4 h, mice were sacrificed and tissues were collected and imaged by the IVIS™
Imaging System (Xenogen Imaging Technologies, Alameda, CA). Samples were fixed in a
10% formaldehyde solution for 2 h and were then washed with PBS. Each treatment was
replicated in three mice to ensure statistical significance. The fluorescence intensity of all
organs was calculated from the images using manual ROI in the Live Imaging 3.1 software.
Tumor growth retardation study and immunohistology analysis
Female nude mice bearing H460 xenograft tumors (size 40–50 mm2) were produced six
days after subcutaneous injection of 5 × 106 NCI-H460 cells on the rear side of the back of
mice. CytC or MPS-cytC in different NP formulations were i.v. injected in each respective
treatment group (160 µg/kg, administered every other day). Tumor growth in the treated
mice was monitored daily by measuring the diameters of tumor with calipers. The tumor
volume was calculated as (W2×L)/2, where W is width and L is length. All mice were
eventually sacrificed by cervical dislocation (after 22 days), and tumor tissues from mice
were collected for immunohistological study. Serotological and hematological factors were
also evaluated to assess toxicity of the various treatments (Table S1). Samples were fixed in
a 10% formaldehyde solution for 2 h and were then washed with PBS. Tumor sections were
prepared by washing tumor tissue with 70% ethanol, embedding the tumors in paraffin and
deparaffinizing the samples in xylene. The sections were then rehydrated in ethanol and
washed in phosphate-buffered saline (PBS). Prepared sections were incubated with a 1:200
dilution of anti-Caspase-3 rabbit serum for 2 h at 25°C. HRP-labeled secondary antibody
(Santa Cruz biotechnology Inc., CA) was added to the blots at a dilution of 1:500 for 20
min. The sections were co-stained with H&E stain and were observed with a microscope
(Nikon Eclipse, Ti-U, Nikon instrument Inc. TX).
Results
NP size and charge characterization
Lipid nanoparticles (NPs) were produced using DOTAP, DOPE, and apolipoprotein (Fig. 1).
Using a Nanosizer, we determined that a 2:1 DOTAP:DOPE molar ratio produced lipid NPs
of optimal size (<100 nm) and highly positive charge (50–55 mV) in an aqueous
environment. Nanoparticles consisting of DOTAP/DOPE and apolipoprotein were smaller
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(20–30 nm) and displayed a lower cationic charge of 25~28 mV, attributed to enhanced lipid
compaction induced by the lipid binding structure of the apolipoprotein. Either MPS-GFP or
MPS-cytC was admixed and attached to the formed NPs during a one hour formulation step.
Protein-loaded NPs were then PEGylated with a mixture of DSPE-PEG2000 and DSPE-
PEG2000-AA (1:1). The resulting final particles, henceforth designated as “MPS-GFP-NP”
or “MPS-cytC-NP” in the text, exhibited a slightly reduced size (20–30 nm) and a
dramatically decreased surface charge (2–3 mV). Nanoparticles produced without DSPE-
PEG2000 were larger and tended to aggregate. All NPs used in subsequent experiments were
produced with a 1:1 ratio of DSPE-PEG2000 and DSPE-PEG2000-AA unless otherwise
explicitly noted.
The NP loading efficiency of MPS-GFP was estimated to be ca. 70 % using a Sepharose CL
6B separating column (Amersham Biosciences, Uppsala, Sweden). Similarly, the NP
loading efficiency of MPS-cytC was determined to be ca. 64–75%. The loading efficiency of
unconjugated GFP or unconjugated cytC in the NPs was determined to be negligible.
TEM and SEM imaging
The NP shape is dependent on the ratio of DOTAP to DOPE and the ratio of HDL
apoliprotein to loaded protein. After NPs were admixed with MPS-GFP protein, negative
TEM staining analysis confirmed the size of the resulting MPS-GFP-NPs to be 20–30 nm
(Fig. 2a). In comparison, MPS-cytC-NPs demonstrated a slightly larger shape (Fig. 2b).
MPS-cytC-NPs and MPS-GFP-NPs appeared to be refined in size with a slightly flattened
morphology. SEM analysis of the NPs adhered on an agarose gel supporting matrix upholds
the notion that MPS-cytC-NPs appear to have a flattened shape (Fig. S1b).
Visualization of MPS-cytC delivery in vitro
After a 6 h treatment with Alexa-488-labeled MPS-cytC-NPs, H460 cells were incubated
with MitoRed (red fluorescence) for 1 hour to stain cell mitochondria. Figure 3 shows partial
surrounding and overlap (yellow) of cell mitochondria (red) by the MPS-cytC protein
(green). This result demonstrates that MPS-cytC proteins transported to the tumor cell by
PEGylated NPs are active around the mitochondria, indicating successful cytC localization
for induction of Caspase-9 dependent apoptotic cascades.
Flow cytometry determination of apoptotic induction
As shown in Supplemental Figure 2, treatment of H460 cells with unconjugated cytC and
free MPS-cytC resulted in cleavage of Caspase-9, indicative of apoptosis. Fluctuations in
cellular levels of AIF or Endo G are characteristic of cellular apoptosis induced
independently of caspase activity [23, 24]. AIF and Endo G, XIAP, and survivin levels in
H460 cell lysates remained constant after MPS-cytC treatment, whereas the levels of
cleaved Caspase-3 and cleaved Caspase-9 increased (Fig. S3). This result suggests that free
MPS-cytC exhibits a penetrating effect in vitro, thereby inducing apoptosis via intracellular
activity.
Using flow cytometry, the expression of annexin V and the permeation of PI were measured
in H460 cells treated for 24 h with either PBS, empty NPs, cytC, cytC + NPs, MPS-cytC, or
MPS-cytC-NPs (Fig. 4). Apoptosis was quantified by the rate of early (Q4) and late
apoptotic cells (Q2). As shown in Table 1, only 1.9% of control cells treated with PBS
exhibited apoptosis. In comparison, apoptosis was induced in 13.4 % and 24.4 % of H460
cells treated with free MPS-cytC and MPS-cytC-NPs, respectively. Significant apoptosis
was not induced by a control cytC+ NP treatment of unconjugated cytC (without MPS)
admixed with NPs.
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In vivo fluorescence biodistribution analysis
Negligible fluorescence was detected in the mouse tumors after 4 h of treatment with PBS,
free GFP, or free MPS-GFP. MPS-GFP delivered by unPEGylated NPs mainly accumulated
in the liver. However, treatment with PEG-AA modified MPS-GFP-NPs resulted in a high
level of fluorescence intensity in the tumor and a comparatively minor intensity in the liver
(Fig. 5a). Confocal microscopy images taken of tumor tissue from mice treated with MPS-
GFP-NPs also show successful tumor delivery of MPS-GFP (Fig. 5b). H460 xenograft mice
were likewise treated with MPS-cytC-NPs, and the biodistribution of the Alexa-488 labeled
cytC was visualized and quantified (Fig. 6). Negligible fluorescence intensity was detected
in mouse tumors after a 4 h treatment with PBS or free cytC. Conjugation of cytC to MPS
resulted in over a 2-fold increase in the delivery of cytC to tumor tissue compared to the
delivery of unconjugated cytC. MPS-cytC-NP treatment resulted in a high level of
fluorescence intensity in the tumor and comparatively a minor intensity in the liver.
Mice treated with NPs admixed with unconjugated cytC (cytC + NP-PEG-AA) showed
tumor accumulation. In the absence of MPS conjugation, cytC delivery in these mice was
probably mediated by non-specific interactions between the respective proteins and the
cationic NPs.
Immunohistochemical staining of Caspase-3
Immunohistochemical results show activated Caspase-3 expression (brown color)
concentrated in tumors from H460 xenograft mice treated with MPS-cytC-NPs (Fig. 7).
Activated Caspase-3 expression is characteristic of apoptotic induction, therefore the results
demonstrate that MPS-cytC carried by the NPs was effective in initiating tumor cell
apoptosis in vivo. Tumor tissues from mice treated with MPS-cytC alone demonstrated a
much lower level of activated Caspase-3 compared to tumors treated with MPS-cytC-NPs.
In vivo tumor growth analysis
We examined whether MPS-cytC-NP treatment provoked anti-tumor growth effects. As
shown in Figure 8a, there was no significant change in tumor growth observed in H460
xenograft mice treated with cytC, cytC +NPs, or empty NPs compared to the PBS-treated
control group. In contrast, treatment with MPS-cytC-NPs provoked a significant decrease in
tumor growth, while free MPS-cytC treatment resulted in partial tumor growth retardation.
The therapeutic success of MPS-cytC-NPs indicates that the NP formulation retains the in
vivo protection and AA-targeting advantages of the NP platform without compromising the
ability of MPS to convey cytC to tumor cells. Increases in the injection dose of MPS-cytC-
NPs resulted in an enhanced therapeutic effect (Fig. 8b). In contrast, injection of xenograph
mice with 160 µg/kg of free MPS-cytC resulted in the maximal therapeutic effect; further
increase in the injection dose did not bring about any improved effect.
Discussion
Effective protein delivery systems hold great potential for treating cancer. However,
challenges hindering the successful delivery of proteins, such as poor blood stability, low
cellular permeability and high liver uptake, have limited the clinical progress of protein
therapeutics [26]. In addition, therapeutic proteins that successfully penetrate into target
cells may become entrapped and degraded within endosomes, preventing release to a
targeted cellular compartment [27, 28]. Cell-penetrating peptides (CPPs) have been shown
to significantly improve protein delivery efficiency, yet these peptides are susceptible to
degradation, especially in the presence of proteases, hampering their use in therapeutic
applications.
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Our intracellular delivery platform uses nanosized DOTAP/DOPE and apolipoprotein
bilayers to provide an effective system for delivering proteins to specific tissues in vivo. We
have determined that a 2:1 mole ratio of DOTAP:DOPE produces small lipid bilayer
nanoparticles. DOPE, a neutral helper lipid, plays an especially crucial role in improving
protein endosomal escape by adopting a hexagonal phase in the endosome lumen that
destabilizes the endosomal membrane [29]. Therefore, we believe that the presence of
DOTAP and DOPE in our NP formulation enables the endosomal escape of attached
proteins, such as cytC, into the cytoplasm of cancer cells [29–33].
Membrane permeable sequences (MPS) can drive protein drugs to a specific site, an ability
enhanced in conjunction with NPs exhibiting a notably strong targeting and protecting effect
due to a DSPE-PEG-AA outer coating [34–37]. We have clearly demonstrated that the
incorporation of this selective ligand allows our NP platform to enhance tumor targeting and
promote greater therapeutic effects in an animal model.
With these surface modifications, the NP shape is highly dependent on external conditions,
such as loaded protein drugs. MPS-cytC-NPs exhibit a different shape than MPS-GFP-NPs
(Fig. 2), an indication that properties such as NP size, net charge, 3D structure and the
presence of loaded protein are important determinants of the NP shape.
MPS-cytC-NP treatment both induced apoptosis in H460 lung cancer cells and prevented
H460 tumor growth in vivo. As shown by the activated Caspase-9 western blots from MPS-
cytC treated H460 cells (Fig. S2) and the localization of the MPS-cytC-NPs proximal to
H460 cell mitochondria (Fig. 3), this result can be explained by the interaction of cytC and
apoptosis-inducing factors in the outer mitochondrial membrane of the tumor cells.
Previously, cytC has been shown to act on the exterior cell structure to decrease apoptosis
and inflammatory reactions related to rheumatoid arthritis [38]. Our study, however,
demonstrates massive H460 tumor cell apoptosis correlated with mitochondrial localization
of fluorescent MPS-cytC after MPS-cytC-NP treatment, demonstrating indirect proof of
successful NP uptake and MPS-cytC delivery to the tumor cell interior.
Fluorescent tissue distribution data confirms the selective targeting of NPs containing MPS-
GFP or MPS-cytC to in vivo tumor sites. Once more, intracellular visualization of the MPS-
cytC or MPS-GFP delivered by the NPs indicates successful endosomal escape and
localization of the proteins in the cytosol of cancer cells. Importantly, selective targeting is
dependent on the co-incubation of the MPS-conjugated therapeutic protein with our NPs.
When mice were treated with MPS-GFP or MPS-cytC admixed with un-PEGylated NPs,
very strong protein signals were observed in the liver (Figures 5, 6). This result is probably
due to the non-specific uptake of unPEGylated NPs by the RES system. In vivo
administration of PEGylated NPs, in comparison, resulted in a longer stability effect and a
lower liver accumulation effect, delivering the loaded protein drug to tumor cells. Overall, in
vivo distribution data clearly demonstrates that the NP formulation can deliver detectable
therapeutic proteins at high efficiency while maintaining low toxicity, suggesting potential
applications in imaging as well as therapy.
NPs admixed with unconjugated-cytC were partially distributed to xenograph tumors in
vivo, whereas free cytC showed little tumor accumulation (Figure 6). One explanation for
this result is that charge-charge interactions between cytC and the NP assist in successful
tumor delivery in the absence of MPS. Treatment of xenograph mice with cytC admixed
with the NPs, however, resulted in 30% lower tumor accumulation levels than MPS-cytC
admixed with NPs. Protein delivery enabled by non-specific interactions between a protein
and its carrier is generally not stable; therefore unconjugated-cytC carried by the NPs would
exhibit a less dramatic cellular uptake or a lower therapeutic effect in vivo. Indeed, the
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transported cytC did not provoke a tumor retardation effect similar to the effect observed in
mice treated with MPS-cytC-NPs (Fig. 8a). This indicates that the force linking
unconjugated-cytC and the NP was not strong enough to enable their co-uptake into tumor
cells.
Conclusions
We have demonstrated the successful production of a nanoparticle platform utilizing
DOTAP/DOPE lipids and an MPS transporting molecule to specifically deliver therapeutic
proteins into tumor tissue. The NP is highly soluble and effective in vitro and in vivo,
enabling the successful delivery of a soluble cytC therapeutic protein. Protein drugs loaded
to the NP can avoid aggregation, which normally results from protein-protein interactions in
vivo. The NPs can be modified with external ligands or protective materials to enhance
targeting and maintain biological stability in vivo. Designed NPs are able to avoid excessive
RES uptake by the liver, deliver cytC protein into cancer cells, moderate protein escape
from endosomal vesicles, and induce apoptosis and tumor growth retardation in vivo. Our
NP promises to be a potent tool for the effective delivery of non-lipophilic therapeutic
proteins for cancer therapy.
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Schematic picture depicting our NP manufacturing platform for protein delivery.
Kim et al. Page 10














TEM images of PEGylated NPs admixed with MPS-GFP (a) and MPS-cytC (b).
Kim et al. Page 11














Uptake and intracellular accumulation in H460 cells after 6 h incubation with Alexa 488-
labeled MPS-cytC-NPs (green) measured using confocal microscopy. Cell nuclei were
stained with DAPI (blue) and cell mitochondria were stained with MitoRed (red).
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Apoptotic induction as detected by Annexin V (x axis) and PI (y axis) staining of H460 cells
after 12 h treatment with different formulations. The percentage of cells in the Q2 and Q4
quadrants is shown in Table 1 and is expressed as mean ± SEM (N=3)
Kim et al. Page 13














Distribution of intravenously administered free GFP, free MPS-GFP, GFP + NP, and MPS-
GFP-NP in major organs (heart, liver, spleen, kidney, lung, tumor) of H460 xenograft mice
imaged using a Xenogen IVIS imaging system. GFP-MPS-NPs were prepared with or
without DSPE-PEG/DSPE-PEG-AA as indicated. A control mouse group was treated with
empty NP-PEG-AA. Organs were imaged using a kinetic IVIS optical imaging program v
3.1 (a). Confocal microscopy images were taken of tumor tissue from mice treated with
MPS-GFP-NP-PEG-AA (b). Blue coloring indicates DAPI nuclear staining while green
coloring represents GFP expression.
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Distribution of intraveneously administered Alexa-488 labeled cytC, cytC + NP, or MPS-
cytC-NPs in major organs (heart, liver, kidney, lung, spleen, tumor) of H460 xenograft mice
imaged using a Xenogen IVIS imaging system. NP formulations were prepared with or
without DSPE-PEG/DSPE-PEG-AA as indicated. Empty NP-PEG-AA, free cytC and free
MPS-cytC served as control treatments. Organs were imaged (a) and quantified (b) using a
kinetic IVIS optical imaging program v 3.1. Error bars indicate the Standard Deviation of
the data.
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Localization of activated Caspase-3 by immunohistochemistry in the tumor sections of mice
treated with PBS (a), empty NP (b), cytC (c), cytC + NP-PEG-AA (d), MPS-cytC (e), and
MPS-cytC-NP-PEG-AA (f). All tissues were stained with Caspase-3 antibody (brown
staining).
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Tumor growth retardation effect of different formulation treatments in an H460 xenograft
mouse model. CytC (40 µg/kg) or MPS-cytC (160 µg/kg) were admixed with NPs and the
resulting particles were further PEGylated with a 1:1 mixture of DSPE-PEG2000 and DSPE-
PEG2000-AA. Each formulation was administered to mice once every two days via i.v
administration (a). The dosage effect of MPS-cytC-NP-PEG-AA in H460 tumor model was
evaluated after intravenous injection every other day. Doses for this study included 80, 160
and 320 µg/kg of MPS-cytC-NP-PEG-AA (P value: * < 0.05, ** < 0.001), Mean ± SEM
(n=5).(b)
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Table I
Quantification of the percentage of H460 cells stained with annexin V and PI after 24 hour treatment with
different nanoparticle formulations. Data was determined from the combined Q2 and Q4 quadrants of Figure 6
and is expressed as mean ± SEM (N=3).
Treatment Q2 + Q4
PBS 1.9 ± 0.8
Empty NP-PEG-AA 2.1 ± 1.0
cytC 4.7 ± 0.8
cytC-NP-PEG-AA 2.2 ± 0.1
MPS-cytC 13.4 ± 3.1
MPS-cytC-NP-PEG-AA 24.4 ± 4.1
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